TNF and chronic obstructive pulmonary disease: However published reports of two clinical trials which examined the effects of the chimeric monoclonal TNFα antibody infliximab (Remicade) in COPD patients found no improvement in symptoms, lung function or reduction of inflammation in induced sputum[45,46].